Compare KOD & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOD | CENT |
|---|---|---|
| Founded | 2009 | 1955 |
| Country | United States | United States |
| Employees | N/A | 6000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2018 | N/A |
| Metric | KOD | CENT |
|---|---|---|
| Price | $38.49 | $43.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $35.43 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 868.6K | 77.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.60 |
| Revenue Next Year | N/A | $2.04 |
| P/E Ratio | ★ N/A | $15.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $28.77 |
| 52 Week High | $47.84 | $45.78 |
| Indicator | KOD | CENT |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 62.16 |
| Support Level | $21.82 | $35.55 |
| Resistance Level | $46.72 | $45.78 |
| Average True Range (ATR) | 2.77 | 1.23 |
| MACD | 0.61 | -0.03 |
| Stochastic Oscillator | 78.56 | 57.04 |
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.